Achilles Therapeutics (ACHL) has released an update.
Achilles Therapeutics has successfully regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. After a challenging period where its shares fell below the $1.00 threshold, the company has managed to stabilize its stock price above this crucial level. This development marks a positive turnaround for the company, reassuring investors of its market standing.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.